Here, we showed that, instead of inhibiting EGFR or EGFR phosphorylation, CAP selectively turned on the ferroptotic program of cancer cells by potentiating EGFR phosphorylation at Y1068 and, concomitantly, enhancing cellular redox level. The gene discussed is EGFR; the disease is cancer.